CN109789204A - 基于her2和her3通路亚型选择乳癌患者药物疗法的方法 - Google Patents
基于her2和her3通路亚型选择乳癌患者药物疗法的方法 Download PDFInfo
- Publication number
- CN109789204A CN109789204A CN201780046794.7A CN201780046794A CN109789204A CN 109789204 A CN109789204 A CN 109789204A CN 201780046794 A CN201780046794 A CN 201780046794A CN 109789204 A CN109789204 A CN 109789204A
- Authority
- CN
- China
- Prior art keywords
- albumen
- activation levels
- expression
- her2
- overall length
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662343555P | 2016-05-31 | 2016-05-31 | |
US62/343,555 | 2016-05-31 | ||
PCT/US2017/035045 WO2017210214A1 (en) | 2016-05-31 | 2017-05-30 | Methods of drug therapy selection for breast cancer patients based on her2 and her3 pathway subtyping |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109789204A true CN109789204A (zh) | 2019-05-21 |
Family
ID=60478927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201780046794.7A Pending CN109789204A (zh) | 2016-05-31 | 2017-05-30 | 基于her2和her3通路亚型选择乳癌患者药物疗法的方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20190219580A1 (ja) |
EP (1) | EP3463462A4 (ja) |
JP (1) | JP2019519772A (ja) |
KR (1) | KR20190015360A (ja) |
CN (1) | CN109789204A (ja) |
WO (1) | WO2017210214A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109734799A (zh) * | 2018-07-23 | 2019-05-10 | 深圳市伯劳特生物制品有限公司 | 一种表达和纯化Her2全长蛋白的方法以及Her2全长蛋白的应用 |
JP7448125B2 (ja) * | 2018-09-21 | 2024-03-12 | 国立大学法人京都大学 | 情報処理方法、コンピュータプログラム、学習済みモデル及び情報処理装置 |
BR112021019376A2 (pt) * | 2019-03-29 | 2021-12-07 | Univ Texas | Compostos com atividade antitumor contra células cancerígenas transportando inserções de éxon 21 de her2 |
EP4051805A4 (en) * | 2019-10-29 | 2023-11-01 | The Board of Trustees of the Leland Stanford Junior University | TREATMENT METHODS BASED ON MOLECULAR RESPONSE TO TREATMENT |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010065568A2 (en) * | 2008-12-01 | 2010-06-10 | Laboratory Corporation Of America Holdings | METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95 |
WO2010132723A1 (en) * | 2009-05-14 | 2010-11-18 | Prometheus Laboratories Inc. | Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy |
CN102016581A (zh) * | 2008-02-25 | 2011-04-13 | 普罗米修斯实验室股份有限公司 | 用抗体阵列选择乳腺癌治疗药物 |
US20120270745A1 (en) * | 2009-07-15 | 2012-10-25 | Prometheus Laboratories Inc. | Drug selection for cancer therapy by profiling signal transduction proteins in ascites or pleural efflux samples |
CN102822676A (zh) * | 2010-01-12 | 2012-12-12 | 雀巢产品技术援助有限公司 | 用于预测三阴性乳腺癌对疗法的应答的方法 |
WO2013033623A1 (en) * | 2011-09-02 | 2013-03-07 | Nestec S.A. | Profiling of signal pathway proteins to determine therapeutic efficacy |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1681983A4 (en) * | 2003-10-14 | 2008-12-10 | Monogram Biosciences Inc | RECEPTOR TYROSINE KINASE SIGNAL PATH ANALYSIS FOR DIAGNOSIS AND THERAPY |
JP2015505959A (ja) * | 2011-12-05 | 2015-02-26 | ネステク ソシエテ アノニム | 癌を有する患者に治療を選択する方法 |
WO2014165855A1 (en) * | 2013-04-05 | 2014-10-09 | Laboratory Corporation Of America Holdings | Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation |
-
2017
- 2017-05-30 JP JP2018562678A patent/JP2019519772A/ja active Pending
- 2017-05-30 CN CN201780046794.7A patent/CN109789204A/zh active Pending
- 2017-05-30 WO PCT/US2017/035045 patent/WO2017210214A1/en unknown
- 2017-05-30 EP EP17807345.8A patent/EP3463462A4/en not_active Withdrawn
- 2017-05-30 KR KR1020187037628A patent/KR20190015360A/ko unknown
-
2018
- 2018-11-28 US US16/202,799 patent/US20190219580A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102016581A (zh) * | 2008-02-25 | 2011-04-13 | 普罗米修斯实验室股份有限公司 | 用抗体阵列选择乳腺癌治疗药物 |
WO2010065568A2 (en) * | 2008-12-01 | 2010-06-10 | Laboratory Corporation Of America Holdings | METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95 |
WO2010132723A1 (en) * | 2009-05-14 | 2010-11-18 | Prometheus Laboratories Inc. | Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy |
US20120270745A1 (en) * | 2009-07-15 | 2012-10-25 | Prometheus Laboratories Inc. | Drug selection for cancer therapy by profiling signal transduction proteins in ascites or pleural efflux samples |
CN102822676A (zh) * | 2010-01-12 | 2012-12-12 | 雀巢产品技术援助有限公司 | 用于预测三阴性乳腺癌对疗法的应答的方法 |
WO2013033623A1 (en) * | 2011-09-02 | 2013-03-07 | Nestec S.A. | Profiling of signal pathway proteins to determine therapeutic efficacy |
Non-Patent Citations (3)
Title |
---|
ALLAN LIPTON等: "HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer", 《BREAST CANCER RES TREAT》 * |
MAURIZIO SCALTRITI等: "High HER2 expression correlates with response to the combination of lapatinib and trastuzumab", 《CLIN CANCER RES》 * |
POOJA ADVANI等: "Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer", 《BREAST CANCER (DOVE MED PRESS)》 * |
Also Published As
Publication number | Publication date |
---|---|
JP2019519772A (ja) | 2019-07-11 |
WO2017210214A1 (en) | 2017-12-07 |
US20190219580A1 (en) | 2019-07-18 |
EP3463462A4 (en) | 2020-07-29 |
EP3463462A1 (en) | 2019-04-10 |
KR20190015360A (ko) | 2019-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11705220B2 (en) | Systems and methods for identifying cancer treatments from normalized biomarker scores | |
Theodoraki et al. | Circulating exosomes measure responses to therapy in head and neck cancer patients treated with cetuximab, ipilimumab, and IMRT | |
Wang et al. | Prognostic role of pretreatment neutrophil-to-lymphocyte ratio in non-small cell lung cancer patients treated with systemic therapy: a meta-analysis | |
Bosma et al. | Efficacy and safety of first-line systemic therapy for metastatic renal cell carcinoma: a systematic review and network meta-analysis | |
Minami et al. | Gustave Roussy immune score and Royal Marsden Hospital prognostic score are biomarkers of Immune-Checkpoint inhibitor for non-small cell lung cancer | |
Landre et al. | Anti-PD-(L) 1 for KRAS-mutant advanced non-small–cell lung cancers: a meta-analysis of randomized–controlled trials | |
CN109789204A (zh) | 基于her2和her3通路亚型选择乳癌患者药物疗法的方法 | |
WO2011088149A2 (en) | Methods for predicting response of triple-negative breast cancer to therapy | |
Kitano et al. | Profiling of phospho-AKT, phospho-mTOR, phospho-MAPK and EGFR in non-small cell lung cancer | |
CN105848678A (zh) | 核酸生物标志物及其用途 | |
Tsukioki et al. | Influences of preoperative metformin on immunological factors in early breast cancer | |
MacNeil et al. | New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified | |
Lehmann et al. | Atezolizumab in combination with carboplatin and survival outcomes in patients with metastatic triple-negative breast cancer: the TBCRC 043 phase 2 randomized clinical trial | |
Zhang et al. | Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases | |
Sheng et al. | Impact of gefitinib in early stage treatment on circulating cytokines and lymphocytes for patients with advanced non-small cell lung cancer | |
Gurbuz et al. | Clinicopathological Factors in Relation to HER2 Status in Metastatic Gastric Cancer: A Retrospective Observational Study | |
Qiu et al. | Expression of EGFR in gastric stromal tumors: a clinicopathologic study | |
Himmetoğlu et al. | Serum levels of growth factors in patients with urinary bladder cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190703 Address after: Vevey Applicant after: Societe des Produits Nestle S.A. Address before: Vevey Applicant before: Nestle Products Technical Assistance Co.,Ltd. |
|
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190521 |